RS
GPCR icon

R Squared’s Structure Therapeutics GPCR Stock Holding History

R Squared’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-680
Closed -$18.4K – 775
2024
Q4 		$18.4K Buy
+680
New +$24.1K 0.02% 918

Other funds holding GPCR

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

R Squared's GPCR Position: Q1 2025 in Review

R Squared sold out of Structure Therapeutics (GPCR) in Q1 2025, closing a stake of 680 shares — an estimated $18.4K sold.

R Squared first reported a position in GPCR in Q4 2024 and held it in 1 quarter. The position peaked at $18.4K in Q4 2024. 150 funds tracked by Wall St. Rank hold GPCR as of Q1 2025.

  • R Squared reported no remaining Structure Therapeutics position as of Q1 2025 after selling out during the quarter.
  • R Squared sold 680 Structure Therapeutics shares in Q1 2025, an estimated $18.4K.
  • R Squared first reported a position in Structure Therapeutics in Q4 2024 and held it in 1 quarter.
  • R Squared's Structure Therapeutics position peaked at $18.4K in Q4 2024.
  • 150 funds tracked by Wall St. Rank held Structure Therapeutics as of Q1 2025.

Based on R Squared's 13F filing for Q1 2025, filed 9 May 2025.